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Conclusion: Salmonella mutant with deletion of 7 nucleotides in 
crp gene was obtained. The special PCR-system for determination 
such mutation was created. 
I P1417 I Antibody Response to Campylobacter 
Antigens in Immunized Mice 
M. Mikhail, Z.S. Mohran, M.O. Wasfj~, B.A. Oyofo, T.E Ismail, 
L.E Peruslu. US Naval Medical Researrh Unit No. 3, Cairo, Egypt 
Objective: Evaluation of Campylobactmjejuni and coli antigenic com- 
ponents which elicit an immune response and identification of classes 
of antibodies stimulated. 
Methods: Five C. jejuni and four coli strains representing a range 
of Lior serogroups and flagellar gene polymorphism groups were 
used to intranasally challenge nine groups of Balb/c mice. Antigenic 
components of each strain were determined by SDS-PAGE and im- 
munoblotting ofbacterial cell onicates (CS) and acid-glycine extracts 
(AGE) with immune mouse serum. 
Results: Protein profiles of CS and AGE showed heterogeneity of 
flagellar proteins (molecular mass (M,) range 58k to 61k) and Mer- 
ences in M, of these and other cellular components. Immunoblotting 
of CS and AGE with homologous and heterologous mouse serum 
demonstrated IgG, IgA and IgM reactions to at least one flagellar 
protein, but only IgA and IgG reactions to outer membrane proteins 
(OMP, M, 20k and 25k) and other cellular components (M, 40k and 
45k) of CS. Immunoblotting of CS with IgG subclasses showed that 
flagellar components were recognized by IgGl , IgG2 and IgG3 anti- 
bodies whereas OMP and other components were only recognized 
by IgGi and IgGz. 
Conclusions: Strain differences observed in protein profiles, in- 
munogenicity and relative antigenicity of protein components were 
not related to Lior serogroup or polymorphc group differences. In 
all strains examined, flagellar proteins showed higher cross-reactivity 
and stimulated all classes and subclasses of antibodies, suggesting their 
involvement in all aspects of host defense, induction of cytotoxicity 
and in protective immunity. 
I P1418 I Analysis of Corynebacterium diphtheriae Toxin 
IgG Antibody in Sera of Healthy Population in 
Poland 
J. Wdory I ,  A. Zakrzewska ', W Gut ', S. Tyski ' . 'Sera and Vacn'nes 
Central Research Laboratory, Warsaw, Poland, 'National Institute .f 
Hygiene, Warsaw, Poland 
Diphtheria is an endemic dlsease in many regions of the world due 
mainly to inadequate health-care delivery systems. The recent out- 
breaks of diphtheria in Belarus, the Russian Federation and Ukraine 
poses a threat to neighbouring countries, including Poland. An in- 
creased incidence of diphtheriae has already been reported in hs 
country. The aim of this study was to standardise an ELISA for the 
determination of speclfic I& against C. diphtheriae toxin, in order to 
measure the protective antibody level in the sera of healthy people. 
The normal level of antibodies against diphtheria toxin in over 400 
serum samples &om healthy population in different age groups (10 
samples each in intervals of one month over the first year of Me and 
then 10 samples each in consecutive years) and adequate diphtheria 
immunisation status was determined. The optimum antigen coating 
dose - 2.5 Lf of diphtheria anatoxin per ml of carbonate buffer pH 
9.6 was estimated. The optimum dilutions for specific IgG determi- 
nation for serum samples and the peroxidase conjugate were defined 
to be 1: lOO and 1:5000 respectively. Antigenantibody incubation 
and conjugate treatment were performed for 1 hour at 37°C. The 
British NBSB diphtheria antitoxin human serum was used as a refer- 
ence. The obtained results of analysed sera were calculated according 
to standard cume. Consecutive vaccination increases anti-diphtheria 
IgG level, what was demonstrated by geometric mean titer calcula- 
tion. The protective antibody level (0.1 JA/ml) in analysed samples 
was calculated for each particular age group. The lack of significant 
protective antibody level was observed in some sera samples of the 
adult group. 
1 P1419 1 The Effect of Immunization with 
"Pervalur"-Tortak (polyvalent urovaccine) 
M. Vignjevit-Krastavtevit 
and Immunology and Virology Erlak, Belgrade, Yugoslavia, 'Institute for 
Renal Diseates, Zvesdara University Hospital, Belgrade, Yugoslavia 
Objectives: "Prevalur"-Torlak is polyvalent vaccine with inactivated 
uropathogenic bacteria. It consists of 7 bacterial strains in appropriate 
concetration. Immunological response and protective efficacy of this 
vaccine have been examinated. 
Methods: Active immunization have been applied in 63 persons, 
mostly female, age 21 to 71 with recurrent urinary tract infection. 
Vaccine was given subcutaneously 3 doses at weekly intervals and 4th 
one month after the 3rd. The titres of specific circulatory antibodies 
were followed on days O., 21. and 45. by agglutination test and total 
amount of IgG, IgA and IgM in serum were determined by RID 
method. All patients were examined during twelve months. 
Results: "Prevalur"-Torlak induces formation of specific antibod- 
ies and the antibody titres increased 4-fold and more in all patients 
after 21th day (mean 1:2.88.39) and 45th day (1:681.39) compared 
to 0th day (1:44.17). This immunization led to significantly higher 
serum IgG and IgA (p < 0.001) in 48 persons. In 26 patients f?e- 
quency of recurrent UTI was reduced from 1 episodall.5 patient 
months to 1 episoda/6.3 patientrnonths, and 38.09% ofpatients were 
without infection during the period of examination. 
Conclusions: Immunization with "Prevalur"-Torlak induces the 
formation of specific antibodies in s i m c a n t  titres in all patients 
and increases of total amount of serum IgG and IgA in 76.19%. 
The protective effect in majority of patients leads to conclusion that 
polyvalent vaccine might be applied safely to the patients su6ering 
&-om UTI. 
G. Da!& I ,  N. Dimkovit *. ' Institute 
Herpes viruses (HSV, VZV, EBV and HHV-6) 
F 1  Susceptibility of Herpes Simplex Virus (HSV) 
to Acyclovir: Absence of Correlation between 
Results Obtained in Vero and MRC-5 Cell Lines 
M. Cotarelo, P. Catalin, C. Shchez-Carrillo. A. Menasalvas, 
M. Rivera, E. Bouza. Hospital General Universitario "Gregorio 
Maraan", Madrid, Spain 
Objectives: To compare the susceptibility of clinical isolates of HSV 
to acyclovir (ACV) on Vero and MRC-5 cells and to evaluate its 
clinical correlation. 
Methods: Susceptibility testing was performed by the "standard" 
method of plaque reduction assay following the American Society 
for Microbiology guidelines on Vero cells as well as on MRC-5 cells. 
We considered a strain resistant when the ICso for ACV was greater 
than 2 fig/&. Three control s t r a i n s  were used, one susceptible to 
ACG: one resistant to ACV and one resistant to ACV and foscarnet. 
Results: Among the 33 isolates of HSV, 21 were susceptible to 
ACV on both cell lines. Twelve isolates were resistant to ACV on 
Vero cells, among them, five were resistant and seven susceptible 
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on MRC-5 cells. We reviewed the clinical records of 12 patients 
with resistant isolates to ACV. Four of those with isolates resistant on 
MRC-5 and Vero did not recover with ACV treatment, however, 
the 6 of the 7 patients with susceptible isolates on MRG5 but 
resistant on Vero cured when treated with ACV. The three control 
strains presented the same susceptibility pattern on both cell lines. 
Conclusions: The absence of correlation between antiviral sus- 
ceptibility of HSV &cal isolates obtained on Vero and MRC-5 
cell lines indicates that there is an urgent need for standardization 
and unification guidelines, specially with the increasing need of an- 
tiviral susceptibility studies due to the introduction and clinical use 
of new antivirals as well as the emergence of resistant HSV isolates. 
I P1421 1 Treatment of Recurrent Herpes Virus Infection 
RM. Semenov, T.I. Dmitrachenko, N.E Akulich. Mtebsk Regional 
clinical diagnosticc laboratory Mtebsk, Belam 
At present there are some preparations developed for treatment of 
recurrent herpes virus infection (acyclovir, valocyclovir etc). These 
drugs have high activity and can reduce the duration of disease but 
cannot prevent it. 72 patients, 59 males and 13 females with genital 
herpes aged 18 to 42 were treated. 24 of them had recurrent herpes 
for 2-3 years, 36 for 3-5 years, 12 more than 5 years. From those 
who had 4-year or more term of disease had recurrences up to 12-15 
times a year 
We used herpes cultural inactivated vaccine (Stpeterburg) for 
treatment in dosage of 0.2 ml each 4 days. 
As a result 38.89% of patients showed clinical recovery after 2-3 
courses of vaccination. There was no dimcal recurrences for 2-3 
years. In 20.8% of patients 3-4 courses of vaccination result in de- 
crease of the recurrences rate. 
1 P1422 I Clinical Reactivation of HSW Difierential Effects 
of Treating First Episodes with Famciclovir or 
Aciclovir 
PD. Woolley. Department .f G U Medicine Withington Hospital, 
Manchesfq UK 
Objectives: To determine whether Merent antiherpes agents af- 
fects future recurrences. 
Methods: Between March 1995 and June 1996, persons with 
first episode genital herpes who attended the STD &c received 
either oral famciclovir 250 mg three times daily or oral acidovir 200 
mg five times daily for five days irrespective of symptom duration, 
severity, wal type, and time since acquisition. All were counselled on 
at least two occasions and advised to return if they had a recurrence. 
Results: Treated persons, viral type, and number returning with 
a recurrence between one and six months after first episode were: 
Famuclwir Adclovir 
HSV-1 20 (45.5%) 33 (46.5%) 
HSV-2 18 (a,%) 27 (38.W) 
No virus grown 6 (13.6%) 11 (15.5%) 
No with returrencc 3 (6.8%) 12 (16.9%) 
Conclusions: This c h c a l  observation suggests that famcidovir 
might induce a state of disabled latency reducing reactivation. 
1 PI423 Recurrence of HSV-2 in Mice Ganglia May 
Relate to Different Effects of Valaciclovir and 
Famciclovir on Establishment of Latency 
H.J. Field, A.M. Thackray. Centrefor Wterinary Sci'ence, Cambridge 
Uniwnity, UK, England 
We have shown that HSV-1 and HSV-2 undergo recurrences of in- 
fection in mice following cessation of valacidovir therapy OID, 173, 
291, 1996; AAC, 40, 846, 1996). When immunosuppression (Cy) 
was applied, virus recurrence was observed in CNS and skin. How- 
ever, without immunosuppression, the recurrence of infectious virus 
was observed in neural tissue only Recurrences occurred even after 
long periods of continuous therapy (up to 20 days p.i.). The time 
that elapses between completion of therapy and the first appearance 
of virus varies among experiments, however, there is usually very 
little variation from mouse-to-mouse w i b  experimental groups. 
In this study we observe that recurrences occurred in the trigeminal 
gangha before virus was detected in the brain stem. Moreover, in 
some groups, while virus replication in gangha was completely sup- 
pressed during therapy, relatively high titres of infectious virus (up 
to 3.8 Loglo virus/gan&) were observed in gangha on cessation 
of VACV treatment. These observations may have a bearing on the 
observed superior effect of famcidovir compared with valaciclovir 
on the prevention of latent infections in mice. 
-1 A Comparison of Famciclovir and Valaciclovir 
Administered at Different Doses in a Murine 
HSV-2 Skin Infection 
A.M. Thackray, H.J. Field. Centrefor Wtetinary %ewe, Cambridge 
Uniwrsity, UK 
We reported previously that famcidovir was superior to valacidovir 
(the oral prodrugs of pencidovir and acyclovir respectively) in a 
murine HSV-2 skin infection model (Thackray & Field, 1996 AAC, 
40, 846-851) when administered by oral gavage at an equal dose 
(50 mg/Kg b.i.d.). The blood concentrations of the active metabo- 
lites (pencidovir or acyclovir) were approximately similar during the 
8 hours following administration of either prodrug (Field et al, 1995 
AAC, 39, 11 14-1 119). The present study investigates the effects of 
varying the dose of the two compounds. Famcidovir or valacidovir 
were a b t e r e d  in the drinking water from 22 h post mfection for 
10 days to provide daily doses &om appm. 20 mg up to 500 mg/Kg. 
The severity of infection, measured by clinical signs, mortahty, weight 
loss, inflamma tion (skin thickness), and daily virus titres in slan, CNS 
or peripheral nerve gangha was reduced by chemotherapy. Famcidovir 
at 20 mg/Kg/day was superior to valaciclovir at 500 mg/Kg/day for 
protection against weight loss and mortality. Furthermore, on cessa- 
tion of therapy, two or three distinct recurrences of infectious virus 
were detected in mice that had been treatedwith valaciclovir; while no 
recurrences followed cessation offamciclovirtherapy even at the lowest 
dose of20 mg/Kg. These results confirm the superiority offamcidovir 
over valaciclovir in this model and point to important differences in the 
mechanrsms by whch the two drug clear the infection. 
I P14251 Valaciclovir for Prevention of Genital Herpes 
Simplex WNS Recurrences - Long-term Safety 
R. Pate1 ' , A.R. Bell * for the International Valacidovir HSV Study 
Group. 'Royal South Hampshire Hospital, Southampton, UK, ' G h o  
Wellcome Research and Development, Middlesex, UK 
Objectives: To assess the safety of valacidovir when used long-term 
for prevention of recurrent genital herpes in immunocompetent and 
immunocompromised individuals. 
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Methods: Adverse events were reviewed for three controlled and 
one open-label c h c a l  trials evaluating the long-term efficacy and 
safety of valaciclovir for prevention of Herpes Simplex Virus (HSV) 
recurrences. 
Results: Studies involving > 1900 immunocompetent patients 
treated for up to one year showed valaciclovir to have a comparable 
safety profile to aciclovir and placebo. Most common adverse events, 
irrespective of treatment, were headache, rhinitis and ‘flu-like’ symp- 
toms and were not considered related to treatment. Only 4 serious 
adverse events were thought attributable to valaciclovir (leukopenia, 
hepatitis) or acidovir (suicidal tendency, muscle weakness). Analysis 
of a double-blind comparison of valaciclovir (1000 mg dady) and 
aciclovir (400 mg twice m y )  for prevention of HSV recurrences in 
1062 HIV seropositive subjects (CD4 cell count >100/mm3) indi- 
cated that over one year, the kequency and nature of adverse events 
were similar to those in immunocompetent indwiduals. There were 
no reports suggestive of thrombotic microangiopathy-hke syndrome 
in this >3000 patient series, includmg those who were HIV seropos- 
itive. 
Conclusions: Valaciclovir (51000 mg daily) a b s t e r e d  for up 
to one year to prevent HSV recurrences shows a similar safety profile 
to aciclovir or placebo in otherwise healthy individuals and those 
immunocompromised due to HIV dection. 
1 PI426 1 Valaciclovir for Prevention of Recurrent Herpes 
Simplex Virus Infection in HIV-Infected 
Individuals - a Double-Blind Controlled Trial 
A.G. Lawrence ’, A.R. Bell for the Valaciclovir International HSV 
Study Group. ’S t  Stephen’s Centre, London, UK, 2Glaxo Wellcome 
Research and Development, Middlesex, UK 
Objectives: To determine the efficacy and safety of valaciclovir for 
the prevention of recurrences of anagenital herpes simplex virus 
(HSV) infection in HIV-idected indwiduals. 
Methods: In an international multicentre study, 1062 
HIV-infected patients with a history of recurrent anogenital her- 
pes were randomized to receive valaciclovir 500 mg twice dady (n = 
358), valaciclovir 1000 mg once daily (n = 355) or acidovir 400 mg 
twice daily (n = 349) for one year. Patients were assessed monthly 
or on recurrence of HSV infection. Treatment ddferences were es- 
timated by intent-to-treat analysis of time to first recurrence using 
Cox’s proportional hazards models. Safety was assessed fiom chical 
chemistry, haematology and adverse event monitoring. 
Results: Treatment groups were evenly balanced for key demo- 
graphc characteristics indudmg CD4 cell count (median 320/mm3) 
and previous HSV recurrence fkequency. Hazard ratios (95% confi- 
dence intervals) for time to first recurrence were 0.72 (0.50, 1.05) 
P = 0.09 for valaciclovir 500 mg twice daily versus aciclovir and 
1.29 (0.93, 1.80) P =  0.13 for valaciclovir 1000 mg once daily versus 
acidovlr, indicating no sigdcant Merences between valacidovir 
and acidovir, but a trend to superiority of valaciclovir 500 mg twice 
daily over aciclovir. The nature and kequency of adverse events were 
sirmlar across treatment groups with most not being attributable to 
study drug. 
Conclusions: Valacidovir is effective and well tolerated for the 
prevention of anogenital HSV recurrences in HIV-mfected indwid- 
Uals. 
1 PI427 I Once Daily Valaciclovir for Prevention of 
S.E. Barton ’, R.J. Crooks2 for the International Valaciclovir HSV 
Study Group. St Stephen’s Centre, Chelsea and Westminster Hospital, 
London, UK, ’Glaxo Wellcome Research and Development, Uxbridge, 
UK 
Objectives: To identlfy clinically effective once dady valacidovir 
regimens for prevention of genital herpes recurrences. 
Methods: Two placebo-controlled, double-blind, randomized 
trials were conducted in otherwise healthy immunocompetent pa- 
tiens with a history of at least 6 genital herpes recurrences per year. 
Both studies evaluated 500 mg once daily valaciclovir, and one m- 
cluded additional assessment of 250 mg and 1000 mg once daily 
regimens. The primary efficacy end-point was time to first genital 
herpes recurrence. Treatment ddferences were estimated using Cox’s 
proportional hazards models. 
Results: Intent-to-treat analyses indicated that all once daily 
valaciclovir regimens slgruficantly prolonged the time to first gen- 
ital herpes recurrence compared with placebo (P -= 0.0001). Hazard 
ratios 195% confidence intervals] for valacidovir 500 mg once dady 
versus placebo in each study were 0.155 [0.11, 0.221 and 0.286 
[0.22, 0.371, indicating that valaciclovir prevents or delays 7144% 
of recurrences. At the end of treatment, 7-8 times more valaci- 
dovir recipients were recurrence-fiee compared with those allocated 
placebo. The safety profile of valacidovir did not M e r  from that of 
placebo in these studies. 
Conclusions: Valaciclovir 500 mg once daily is highly effective 
and safe for the prevention of recurrent genital herpes episodes, 
providmg a more convenient, simple and discreet dosing regimen 
than is currently available. 
Genital Herpes Recurrences 
lp14281 A Recombinant Glycoprotein 6-2 Based Assay 
for Type-Specific Detection of Antibodies to 
Herpes Simplex WNS Type 2 
E. Spranzi ’ , E Corno 
Biomedica Diagnosticr, Saluggia, Italy, 21nstitutfur Med.  Mibrobiologie 
und Immunologie, Rheinixhe Friedrich- Wilhelms- Uniuersitijt, Bonn, 
Germany 
Herpes simplex virus types 2 and 2 (HSV-1, HSV-2) are closely related 
viruses. Most of their homologous proteins are highly conserved and 
therefore elicit cross-reactive antibodies that make Mlcult to define 
accurately the presence of specific HSV-2 antibody, specially in sub- 
jects previously infected by HSV-1. Recently glycoprotein G (gG) 
of HSV-2 and HSV-1 have been shown to present highly dtfferent 
aminoacid sequences and to be a predominantly type-specific target 
of human humoral response. Development of commercial serologic 
tests based on purhed gG-2 protein has evidenced its usefulness 
for more reliable measurements of HSV-2 antibodies. To overcome 
the problems in preparing standadzed and purified native proteins, 
the gG2 protein was expressed in the baculovirus expression sys- 
tem. Here we describe an indirect ELISA assay, for detection of IgG 
antibody, developed with the recombinant gG-2 construct and the 
pre- results of the clinical evaluation. Of 19 patients with cul- 
ture-proven HSV-2 mfection, 18 were reactive for gG-2 IgG. Assay 
specificity was 99% as demonstrated by testing sera from 34 patients 
with culture pmven HSV-1 infection, 13 HSV antibody-negative m- 
dividuals and sera from 102 children between 2 and 6 years of age. 
Further study will be required to determine relative sensitivity and 
specificity of the assay but the results suggest that the recombinant 
gG-2 protein based assay can be a suitable method for diagnosis of 
HSV-2 infections. 
S. Enrietti I ,  A.M. Eis-Hiibinger *. ’ Sorin 
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I PI429 I Complicated Varicella Infection 
L. Sakalauskaite, L. Petiuliene. Mlnius Univenify Children’s Hospital 
( W C H ) ,  Lithuania 
1993-1997 at the intensive care unit of W C H  there were treated 
19 children with complicated varicella. By age the patients may be 
grouped 4 infants, 1-3 year-2 children, 3-7 year-10, 7-11 year-3. 
Varicella complications were observed: a) neurologic: cerebellitis, 
encephalitis, meningoencephalitis-9 cases, b) purulent infections-7 
cases; 1 patient had varicella and gastroenteritis. 4 children had al- 
lergic factor and 3 children had unfavourable premorbidity condi- 
tions in neonatal period. Complications were revealed in the period 
between the 3 and the 8 days after the first signs of rash. The pa- 
tients were in a fever, complained of a headache and limpness, were 
vomiting and then manifested seizures and cerebellar ataxia. Blood 
examination revealed a marked leucocytosis, thrombocytopenia, for- 
mula left deviation, t ERS. Blood cultures analysis was made for 12 
patients: S. aureus - 3 cases, S. epidermidis - 2, Streptococrus pyogenes - 
1, Ps. aeroginosae - 1, in the remaining cases the result was negative. 
For treatment of purulent complications we used penicillini &up 
preparations (100-200 mg/kg/daily), preparations of cephalosporin 
group (100 mg/kg/daily) and aminogkcozide (4 mg/kg/daily). For 
treatment of neurologic complications we used oral/parenterall zovi- 
m treatment (50 mg/kg/2x daily). For treatment of neurologic and 
purulent complications we used short 1-3-day courses ofintravenous 
immunoglobulin and prednisolone. 
Conclusions: 1. Varicella complications is related to the patient’s 
age. 2. Good results were achieved when zovirax and i/v IgG were 
used at the earliest stages. 3. Most of varicella complications were 
neurologic. 4. All patients with complicated varicella recovered. 
Central Nervous System (CNS) Complications 
of Varicella in lmmunocompetent Children. A 
Ten-Year Muiticentre Survey in Italy 
R. Manfkedi, E Chodo for the Acyclovir-Chickenpox Italian Study 
Group. Department of Experimental and Clinical Medicine, Division of 
Infectiota Diseases, Univmity of Bologna, Bologna, Italy 
Objective: To assess the fiequency, dinical spectrum and outcome 
of CNS complications of chckenpox in immunocompetent children 
hospihed  during the last decade. 
Methods and Results: In a retrospective study of 219 otherwise 
healthy patients @) hospitalized for 247 different varicella complica- 
tions in 10 Dept. ofpediatrics and Infectious Diseases, CNS involve- 
ment was recognized as the most fiequent complicating event (104 
episodes: 42.1% of overall varicella complications). CNS involve- 
ment occurred more fiequently in males compared with females (66 
cases vs. 3 8 ; p  < 0.04, x2 test), and a remarkable kquency ofinhafa- 
miliar exposure to VZV was seen (35 p of 104: 33.7%). The clinical 
picture included encephalitis or nevrassitis in the large majority of 
p (101 of 104). with predominant cerebellar involvement in 65 p; 
2 cases of polyradiculoneuritis and one case of bacterial meningitis 
were observed in the remaining 3 p. CNS complications occurred 
at a more advanced mean age (6.6 Zt 2.8 years), compared with the 
involvement of lower respiratory tract and skin/soft tissues (mean 
3.5 f 1.8 and 4.3 f 2.2 years, respectively; p < 0.001, Student t 
test), and appeared later during disease course (after 7.4 f 2.6 days 
vs. 3.2 f 1.5 and 3.8 f 1.8 days for pulmonary and skidsoft tissues 
involvement, respectively; p < 0.001). All cases of CNS involvement 
had a favourable outcome within 5-40 days (with complete cure), al- 
though their occurrence led to a prolonged hospitalization (mean 7.9 
3t 6.8 days). After complication onset, 67 p received i.v. acyclovir and 
7 anti-VZV lg, but they didn’t obtain sigdcant benefits as to dura- 
tion and severity of clinical picture, when compared with untreated 
p. Disrussion: Although chickenpox is considered a t r i d  disorder 
in healthy children, when evaluating hospitalized p a considerable 
fiequency of CNS complications may be observed, often responsible 
of prolonged admission and need of additional care. A hgher inci- 
dence of CNS complications and a surprisingly greater fkquency in 
the male gender were observed in our experience, compared with 
previous reports. Although including numerous cases of encephal- 
tis without cerebellar ataxia, an udormly favourable prognosis was 
observed. The delayed occurrence of CSJS disorders may reflect 
their fiequent immune-mediated pathogenesis. Bacterial meningitis 
has not been reported until now in association with chickenpox. 
Acyclovir &d not prove effective in reducing the kquency and the 
severity of these complications; however, hrther studies are needed 
with early administration of this drug to p with a presumed higher 
risk to develop a complicated disease. 
I PI431 1 Oral Acyclovir Prophylaxis of Varicella after 
Intimate Contact 
Y.C. Huang’, T.Y. Lin’, H.C. Ning*. ‘Chang Gung Children’s 
Hospital, Taiwan, R O C ,  ’Chang Gung Memorial Hospital, Eiwan, 
R O C ,  3Kweishan, Taiwan, ROC 
Objectives: Whether oral acyclovir (ACV) given in late incubation 
can prevent c h c a l  varicella or not. 
Materials and Methods: Twenty-seven lnfants and children sus- 
ceptible to varicella received oral acydovir (ACV) (40 mg/kg dady 
in 4 divided doses) for 5 days, starting 9 or 11 days after expo- 
sure h m  the index case in the family (2 in the classroom). The 
clinical features were compared with 13 control children who did 
not received ACV Enzyme-linked immunoassay method was used 
to detect varicella-zoster virus (VZV) antibody and, in follow-up 
immunologic studies, lymphocyte proliferative response was added. 
In some cases, blood culture and polymerase chain reaction with 
Southern hybridization were used for detection of viremia. 
Results: Among the 27 chddren in treatment group, two (7.4%) 
developed the disease, while seroconversion was observed in 19 sub- 
jects (70%). Follow-up immunologic studies in 12 of these 19 sem- 
converted subjects 30 months later showed persistent cellular and/or 
humoral immunity to VZV Only one subject, bled 11 days after 
exposure, had positive VZV DNA and blood culture for VZV On 
the other hand, 10 of 13 (77%) control subjects developed ckrucal 
varicella. 
Conclusions: We consider that oral ACV administration at the 
beginning of secondary viremia in late incubation period (9 days 
after exposure) can effectively prevent, or mod& clinical varicella. 
I PI432 I Valaciclovir Versus Aciclovir in Herpes Zoster 
Ophthalmicus 
T. Hoang-Xuan’, D. Chiche ’, C. de Labareyre3, J. Colin*. 
‘Hopital Bichat Paris, France, ’Hopital Morvan Brest, Franre, 
3Laboratoire Glmo Wellcome Paris, France 
Objectives: To compare valaciclovir (the L-valyl ester of aciclovir) 
and acidovir treatment on the incidence of ocular complications in 
patients with acute herpes zoster ophthalrmcus. 
Methods: We performed a multicentric randomized, dou- 
ble-blind study in 121 immunocompetent patients. Each patient re- 
ceived oral aciclovir (800 mg 5 times daily) or valaciclovir (1000 mg 
3 times daily) starting within 72 hours of skin eruption for 7 days. 
Pain intensity and severity were assessed for 6 months. Ophthal- 
mological examination was performed 5 times during the first two 
weeks, weekly during the first month and monthly und week 24. 
S m t y  females and 61 males, aged h m  21 to 95 years (mean 60 years, 
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SD 19 years) were included. Patients characteristics were comparable 
at e n q .  
Results: Incidence of keratitis, uveitis and episderitis was sim- 
ilar in the two groups, Neither neurotrophic keratitis nor scleritis 
were reported. 43 patients in the valacidovir group versus 41 in the 
aciclovir group were totally healed at day 14. At day 10, 39% of 
patients in the valaciclovir group and 50% in the aciclovir group had 
pain. Only 3 patients in each group complamed of pain at week 24. 
Drug-related adverse events were reported in 4 patients (7%) of each 
group. 
Conclusions: Valaciclovir showed s d a r  efficacy to adclovir on 
the skin lesions and ocular complications of herpes zoster ophthalmi- 
CUS, and a similar safety profile. Valaciclovir therefore provides an 
alternative to acidovir in herpes zoster ophthalmicus with the ad- 
vantage of simpler 3 times daily dosing. 
I PI433 I Effect of Early Versus Late Therapy of Acute 
Herpes Zoster on Prolonged Pain 
M.J. Wood’, S .  Shukla2, A,€? Fid&an2. ’Birmingham Heartlands 
Hospital, VK, 2GLUCo Welkome Research and Development, Uxbridge, 
U K  
Objectives: To estimate the efficacy of antiviral therapy when given 
early (548 hours) or late (48-72 hours) after rash onset. 
Methods: Two large databases (n = 1030) from randomized con- 
trolled stucLes were reviewed. In patients > 18 years of age, acidovir 
was compared with placebo. In patients 1 5 0  years of age, valaciclovk 
was compared with aciclovir. 
Results: Treatment Merences for complete resolution of 
zoster-associated pain and median pain duration were: 
Start of treatment M e d m  pan  duration (days) Aciclovir VI placebo 
Acidovir Placebo HR 
(n = 133) fn = 137) (95% CI) 
Early 03%) 22 62 1.58 (1.12. 2.22); P =  0.009 
Late (27%) 21 67 1.83 (1.10, 3.05); P =  0.02 
Start of treatment Medin pan duration (days) Vdacidovir vs acidovlr 
Vdacidovir Placebo HR 
(n = 384) (n = 376) (95% CI) 
Early (62%) 44 51 1.28 (1.03, 1.60); P =  0.03 
Lace (38%) 36 48 1.40 (1.04, 1.87); P =  0.02 
(HR = h a r d  nno; CI = contidcnce in ted)  
Conclusions: Both valaciclovir and acidovir provide signifcant 
advantages on shortening pain duration even when therapy is delayed 
up to 72 hours after rash onset. Valaciclovir is clearly superior in ths 
regard. They are the only antivirals to have shown such benefits 
beyond 48 hours. Given these results, a placebo-controlled study is 
ongoing to determine the benefit of valaciclovir on pain cessation 
with therapy starting beyond 72 hours. 
I PI4341 A PCR-Based Assay to Assess Mutations in the 
Thymidine Kinase Gene of varicella zoster vims 
( Vzv) 
l? Chatellard 
R. Sahli . ’Centre Hospitalier Universitaire Vaudois, Lnusanne, 
Suritzerfand, ’H3pitaux de Lyon, France, 3H6pital Universitaire de 
Genbe, Switzerland 
Mutations in the thyrmdine kinase (tk) gene of v m  are associated 
with resistance to acyclovir. Plaque reduction assays are often used 
D. Thouvenot 2,  W Wunderli 3,  l? Meylan 
to idenhfy resistant vzv  strains. This technique is time-consuming 
and may lead to the loss of mutants if the starting material is con- 
taminated with a wild type (wt) s-, or if a revertant emerges in 
the primary culture. To overcome this difXculty, we have set up a 
detection system which allows the identification of tk mutations in 
viral DNA from a clinical sample without virus propagation. In ths 
system, we use the polymerase chain reaction (PCR) to amplify the 
complete tk open reading b e .  The sense primer contains a T7 
RNA polymerase promoter which allows in vitro transcription of 
the amplified tk DNA. Following PCR, the DNA w e n t  is di- 
rectly added to a coupled transcription/translation reaction derived 
from a wheat germ extract containing a radioactive amino acid. After 
electrophoretic separation in a polyacrylanude gel, the tk proteins are 
detected by autoradiography. Nonsense or h e s h i f i  mutations lead 
to a truncated form of tk, dearly distinct from the wt, as illustrated 
by the analysis of a resistant strain of v m  Missense mutations, not 
detected by this assay, could possibly be identified by analysis of tk 
activity in vitro. 
ml Seroepidemiological Study of Epstein Barr 
Virus Infection in Vojvodina 
S .  Brkit, J. Jovanovit. Clinicfor Infectious Diseases NoviSad, Yugoslavia 
The aim of our study was to screen epidemiological situation about 
EBV infection in our province and to evaluate efficasy of IgG 
EBWCA as a marker of EBV infection in comparation with IgG 
EBVNA. We collected 171 sera from voluntary blood donors and 
chddren and performed ELSA IgG to EBWCA and EBVNA. We 
found 148 (86%) positive and 23 (13.45%) negative IgG EBWCA 
sera. The incidence of IgG EBWCA negative results slowly de- 
creised &om age group 0-5 (42.85%) to 6.25% 26-30 year group. 
Among IgG EBWCA negative sera we found even 8 (34.78%) 
IgG EBVNA positive sera specially in older patients. Average age 
of patients with IM in Vojvodina is 16 year old and in this group 
we found only 11% of negative sera. We conclude that majority of 
EBV infections are asymptomaticly aquired before 16 year old and 
our province depende to group of developed or middle developed 
countries. IgG EBVNA are more efficacy in epidemiological inves- 
tigations than IgG EBWCA. 
I PI436 I Treatment of EBV B Cell Lymphoproliferative 
Disorder with Anti-I16 Monoclonal Antibody 
E. Pachanov’.’, E. Haddad2, J.-L. Casanova2, E Dulieu2, 
S. Blanche ’, I. Resnick 
Institut ofpediatric Hematology, Moscow, Russia, ’Unite d’lmmunologie 
et d’Hematologie, Hopital dec Enfants Malades, Pans, France 
Objectives: To test efficiency and safety of anti-Jl-6 monoclonal an- 
tibody (Mab) in therapy of EBV B cell lymphoprohferative &order 
(BLPD) following BMT. 
Methods: A 5-years old boy with f d  lymphohstiocytosis 
was conditioned and received the T & B cell-depleted marrow 
from his HLA-mismatched EBV+ father. After the graft failure 
he was reconditioned and transplanted with his HLA-mismathed 
EBV+ mother’s depleted marrow. No GVHD prophylaxis was given. 
He had engraftment on day +28. On day +75 he developed a 
biopsy-proven EBV BLPD. 
Results After the anti-11-6 Mab (B-E8) administration on day + 
100 (0.4 mg/kg/day for 15 days) the BLPD resolved. He is currently 
well (1 year after BMT), with no signs of EBV BLPD. 
Conclusions: T h  case report confirmed the efficacy and the 
safety of anti-11-6 Mab as first-line therapy of BLPD. 
A. Fischer’. ‘Department of BMI; Russian 
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I PI437 I Simuttaneous Detection of Mononucleosis 
Syndrome Serology Madcers Using an EIA 
Dipstick System 
B. Kiehl', E. Lennette'. 'GenBio, San Diego, C A ,  USA, 
Berkelq: C A ,  USA 
Objective and Methods: Dipsticks detecting IgG to Epstein-Barr 
virus viral capsid antigen (VCA), Epstein-Barr virus recombinant 
nuclear antigen type-1 (EBNA-l), cytomegalovirus (CMV) and tox- 
oplasma and IgM to heterophile, EBV-VCA, and CMV are evaluated 
and compared to latex (heterophile), indirect immunofluoresence 
(IFA) and enzyme immunoassay (EIA) results. 
Results: Six (1.8%) out of four hundred twenty-five samples sub- 
mitted from patients with suspect mononucleosis syndrome were 
heterophile latex positive and the dipstick product classified all as 
positives. The corresponding EBV profiles supported EBV mononu- 
cleosis for all eleven samples. One (0.3%) additional sample is identi- 
fied as a current or recent EBV infection based on VCA-IgG reactiv- 
ity and EBNA-IgG nonreamvity. An additional 25 (7.6%%) samples 
are CMV IgM reactive. Twenty samples (6.0%) that are neither EBV 
nor CMV reactive and twoplasma IgG were detected. 
Conclusions: Agreement between individual assay methods are 
all greater than 90%. Simultaneous detection of all EBV mononu- 
cleosis syndrome markers is feasible. Additionally, detection of a sig- 
nificant number of primary and/or recurrent CMV infections that 
presumably may cause the mononucleosis episode is illustrated. 
Virolab, 
1 PI438 I Comparison of lmrnunofluorescence with 
Enzyme lmmunoassay f o r  Detection of Semm 
Immunoglobulin G Response to Human 
Herpesvirus 6 
E Mesa, F! Campo, A. Guerra-Neira, R. Martinez-Zapico. Dpt. of 
Microbioloa, La Par Hospital, Madrid, Spain 
Objectives: To evaluate indirect immunofluorescence assay (IFA) 
and enzyme immunoassay (EIA) for the detection of immunoglobu- 
lin G antibodies to human herpesvirus 6 (HHV-6). 
Methods: We tested 250 serum samples by IFA (HHV-6 IgG IF1 
Kit, Bios GmbH, Miinchen, Germany) and EIA (HHV-6 IgG EIA, 
Biotrin International, Dublin, Ireland). 
Results: The fkquency of distribution of the samples according 
to IFA test titers and results obtained by EIA were: 
IFA test tircr No. of serum rvnpln No. posiovc by EIA (%) No. negative by EIA ( O h )  
N@VC 
1/20 
1/40 
1/80 
11160 
1/360 
11640 
1/1280 
I"eSpCdf,C 
65 
62 
22 
48 
14 3
9 
5 
12 
16 (24.6) 
29 (46.8) 
42 (87.5) 
13 (93) 
13 (100) 
12 (54.5) 
9 (100) 
5 (100) 
'2 (100) 
49 (75.4) 
33 (53.2) 
10 (45.5) 
6 (12.5) 
1 (7.1) 
0 
0 
0 
0 
Conclusions: We have found discrepancies in the results obtained 
by IFA and EIA, mainly when low titers resulted by IFA analysis. 
Viral hemohagic fevers 
-1 Coagulation Disorders in Children with Viral 
Hemorrhagic Fever 
E.C.M. v a ~ ~  Gorp', C. Suharti', T.E. Setiati', M.S. Trastotenojo3, 
H. ten Cate 
D.P.M. Brandjes '. 'Department ofhternal Medicine Slotemart hospital 
Amsterdam, Netherlands, ZDepartment of Internal medicine Univmity of 
Diponegoro Semarang, Indonesia, 'Pediatric department Uniwnity of 
Diponegoro Semarang, Indonesia, 4Department of Internal medicine 
Catholic University Nimegen, Netherlands, 5Centerfor hemostasis, 
thrombosis, atherosclerosis and infimmation, A M C ,  Amsterdam, 
Netherlands 
Objectives: Viral hemorrhagic fever e.g. Dengue hemorrhagic fever 
PHF) ,  is an acute febrile disease complicated by bleeding and/or 
shock. Activation of the coagulation cascade and fibrinolysis is stud- 
ied in a p u p  of children with severe hemorrhagic fever. 
Methods: During the period JulyIOctober 1996 all children (28) 
admitted to the intensive care unit with the clinical diagnosis of 
Dengue hemorrhagc fever enrolled the study. Patients were clin- 
ically classified as DHF I11 and N, according to WHO criteria. 
Markers of coagulation and fibrinolysis were sampled on three suc- 
cessive days, starting at the day of admittance and one sample on the 
day of discharge. 
Results Eight patients died. Mean age of all patients 6.5 years. 
Early in the &ease there was an evident increase in markers of 
thrombin generation. (values at day of adnuttance, SUMVOK vs. 
deaths). F1 + 2 hgments (median 2.4 vs. 5.9; p < 0.05; normal 
cl.1 nmolll), TAT complexes (median 22 vs. 81 mg/l; p < 0.05; 
normal t4 .1  mgll), fibrinogen was decreased (mean +- sd 1.6 
+- 0.8 vs. 1.4 +- 0.3 gfl; ns; normal 1.7-4.0 gll),. Fibrinolysis 
increased during hospital stay, most obvious in the non SUMVOK, 
measured as D h e r s  (third day after admittance, median 457 vs. 
649 ng/ml; p < 0.05; normal <39 ng/ml). 
Conclusions: Hemorrhagic fever in children is characterized by 
dmeminated intravascular coagulation PIC) ,  probably one of the 
contributive factors to the often dramatic outcome. 
M. Keuter ', W, Dolmans ', A. van der Ende ', 
I PI440 I Disorders of Hemostasis and Fibrinolysis in the 
Hemohagic Fever 
DZ. eengit, E. B e w t ,  S. TelalbaSit, N. Koluder. Clinic infem'ous 
diseases, Sarajevo Institute Med. University, Sarajevo, Bosnia 
In 57 patients suEering h m  hemorrhagic fever /Hantaan = Pum- 
malla virosis/hemostasis and fibrinolysis were followed. The analysis 
showed the fkquent acceleration of trombocitopania and fibrinoly- 
sis. The most frequent was trombocitopenia-at 32 patients, primary 
trombocitopenia 19, and secondary 13. Fibrinolysis was acceleration 
in 25 out of 57 observed patients, DIC was detected at two patients. 
Primary fibrinolysis is more &quently/l5/, secondary at 10 pa- 
tients. It was more kequently venfied at the onset of the disease, 
when the greatest acceleration was noticed 98/min with the ap- 
proximate one of 116. In the later course of the disease, fibrinolysis 
was present together which the developed azotemia &ve the grave 
course of disease. It was noticed that early fibrinolysis had more 
benign course. Also, trombocitopenia and fibrinolysis in this stage 
were shorter in duration and endid without the therapy, while the 
secondary with azotemia can provoke malignant bleeding, because 
of which it was necessary to apple antiplasmin in fibrinolysis, or 
heparin in DIC. 
